Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.
Br J Dermatol
; 166(2): 417-21, 2012 Feb.
Article
em En
| MEDLINE
| ID: mdl-21848685
ABSTRACT
BACKGROUND:
Bosentan is an oral dual endothelin receptor antagonist, which has been shown to be efficacious for preventing new digital ulcers in patients with systemic sclerosis (SSc) in two high-quality randomized controlled trials. However, its efficacy for nondigital ulcers in SSc remains unknown.OBJECTIVES:
To evaluate the efficacy of bosentan on nondigital ulcers in patients with SSc.METHODS:
Bosentan was administered to five patients with SSc with pulmonary arterial hypertension, who also had nondigital ulcers refractory to conventional treatments. The efficacy of bosentan on nondigital ulcers and its association with clinical features of ulcers were analysed.RESULTS:
The nondigital ulcers refractory to conventional treatments were significantly improved by the administration of bosentan in cases surrounded with severe cyanosis. In contrast, nondigital ulcers without cyanosis were still refractory to bosentan therapy.CONCLUSIONS:
Bosentan may be efficacious for accelerating the healing of nondigital ulcers with severe cyanosis, suggesting that nondigital ulcers caused by severely impaired peripheral circulation are highly responsive to this treatment.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Escleroderma Sistêmico
/
Sulfonamidas
/
Úlcera do Pé
/
Fármacos Dermatológicos
/
Anti-Hipertensivos
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Br J Dermatol
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Japão